Myelodysplastic Syndromes-Many New Drugs, Little Therapeutic Progress

被引：11
作者：
Tefferi, Ayalew [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA
来源：
MAYO CLINIC PROCEEDINGS | 2010年 / 85卷 / 11期
关键词：
ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; IRON CHELATION-THERAPY; HIGH-RISK; PHASE-III; PROGNOSTIC-FACTORS; SCORING SYSTEM; SERUM FERRITIN; UNITED-STATES; 5Q DELETION;
D O I：
10.4065/mcp.2010.0502
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1042 / 1045
页数：4
相关论文
共 50 条
[21]   Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes [J].
Zou, Jixue ;
Zhou, Zhigang ;
Wan, Liping ;
Tong, Yin ;
Qin, Youwen ;
Wang, Chun ;
Zhou, Kun .
PLOS ONE, 2015, 10 (08)
[22]   Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape [J].
Schwind, Sebastian ;
Jentzsch, Madlen ;
Kubasch, Anne Sophie ;
Metzeler, Klaus H. ;
Platzbecker, Uwe .
NEOPLASIA, 2021, 23 (11) :1101-1109
[23]   Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints [J].
Hidalgo-Lopez, Juliana E. ;
Kanagal-Shamanna, Rashmi ;
Quesada, Andres E. ;
Thakral, Beenu ;
Hu, Zhihong ;
Mitsuhashi, Takayuki ;
Yabe, Mariko ;
Garcia-Manero, Guillermo ;
Bueso-Ramos, Carlos E. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 :S16-S25
[24]   Progress in the Genetics of Myelodysplastic Syndromes with a Latin American Perspective [J].
Basquiera, Ana Lisa ;
Andreoli, Veronica ;
Grille, Sofia ;
Belli, Carolina Barbara .
GENES, 2025, 16 (06)
[25]   What are the most promising new agents in myelodysplastic syndromes? [J].
Chandhok, Namrata S. ;
Boddu, Prajwal C. ;
Gore, Steven D. ;
Prebet, Thomas .
CURRENT OPINION IN HEMATOLOGY, 2019, 26 (02) :77-87
[26]   Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress [J].
Venugopal, Sangeetha ;
Shallis, Rory M. M. ;
Zeidan, Amer M. M. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (09) :903-911
[27]   Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes [J].
Wang, Chen ;
Sallman, David. A. A. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (05) :387-408
[28]   First-line Therapeutic Strategies, for Myelodysplastic Syndromes [J].
Santini, Valeria .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 :S31-S36
[29]   Targeting the Myeloid Lineages and the Immune Microenvironment in Myelodysplastic Syndromes: Novel and Evolving Therapeutic Strategies [J].
Chung, Clement .
ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) :475-487
[30]   Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes [J].
Montalban-Bravo, Guillermo ;
Garcia-Manero, Guillermo ;
Jabbour, Elias .
CURRENT OPINION IN HEMATOLOGY, 2018, 25 (02) :146-153
12345